[Can alcoholic withdrawal delirium be prevented?].
In alcohol-dependent in-patients, an adequate drug prophylaxis should be made in order to lower the degree of a developing alcohol withdrawal syndrome (AWS) or to prevent a life-threatening delirium tremens. Pre-condition of successful therapy is a precise diagnosis. In patients, the beginning of whose abstinence is known, carefully-targeted pharmacological interventions can prevent severe imbalances of neurotransmitters. Typical time courses of destabilisation of neural balances should be considered. Since there is no single drug which is able to influence various transmitter systems, normally the use of drug combinations is necessary. In ENT-patients, traumatologic patients and patients from the department of maxillo-facial surgery, screening methods based on a simply-structured questionnaire relating to information from the patient and his surroundings and selected laboratory parameters should be used. High-risk patients who could get an AWS or delirium tremens should be treated prophylactically during their oral premedication period. Important drugs for successful prophylaxis of an AWS are benzodiazepines, clonidin, magnesium and vitamin B 1. A close-meshed control of the glucose metabolism, electrolyte and acid-base balance should be performed. Neuroleptica can be used if there is any indication for their adjuvant use. In severe cases that require deep sedation or hypnosis, propofol or gamma-hydroxy-butyric acid should be used. Perioperative infusion of alcohol as a prophylactic agent against delirium tremens is regarded as an obsolete therapeutic measure for ethical reasons and because equally good or better results can be achieved by carefully-targeted drug therapy. Due to its easy use, however, the application of alcohol has not yet completely disappeared from the therapeutic spectrum.
Hensel
M
M
Klinik für Anästhesiologie und operative Intensivmedizin der Charité, Humboldt-Universität zu Berlin.
Kox
W J
WJ
D000430:Alcohol Withdrawal Delirium / Q000209:etiology / Q000517:prevention & control*; D000437:Alcoholism / Q000175:diagnosis*; D014151:Anti-Anxiety Agents / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000008:administration & dosage; D001569:Benzodiazepines; D001921:Brain / Q000187:drug effects; D003000:Clonidine / Q000008:administration & dosage; D016292:Procedural Sedation; D006801:Humans; D008274:Magnesium / Q000008:administration & dosage; D018377:Neurotransmitter Agents / Q000378:metabolism; D010343:Patient Admission; D011183:Postoperative Complications / Q000209:etiology / Q000517:prevention & control*; D013831:Thiamine / Q000008:administration & dosage
D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D018377:Neurotransmitter Agents; D001569:Benzodiazepines; D008274:Magnesium; D003000:Clonidine; D013831:Thiamine